Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions, a biopharmaceutical company, has announced that the Drugs Controller General of India has issued a registration certificate for BioThrax, which enables the marketing and sale of the vaccine in India to help prevent anthrax infection.
Subscribe to our email newsletter
Emergent BioSolutions has signed a marketing agreement with Biological E for the marketing of BioThrax in India. BioThrax is the only vaccine for the prevention of anthrax infection licensed by the FDA, the company said.
Fuad El-Hibri, chairman and CEO of Emergent BioSolutions, said: “The Government of India has been explicit in expressing its commitment to protect its population from the continuing threat of bioterrorism. We are certainly pleased that BioThrax will be a valuable countermeasure available to the Government of India to achieve that goal.”